Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

1. Family Caregiving for Individuals With Heart Failure: A Scientific Statement From the American Heart Association

Family Caregiving for Individuals With Heart Failure: A Scientific Statement From the American Heart Association Family Caregiving for Individuals With Heart Failure: A Scientific Statement From the American Heart Association | Circulation Search Search Hello Guest! Login to your account Email Password Keep me logged in Search Search June 2020 May 2020 April 2020 March 2020 February 2020 January 2020 This site uses cookies. By continuing to browse this site you are agreeing to our use (...) of cookies. Free Access article Share on Jump to Free Access article Family Caregiving for Individuals With Heart Failure: A Scientific Statement From the American Heart Association , PhD, RN, FAHA, Chair , DNP, ANP, FAHA, Vice Chair , PhD, RN , PhD, RN , MD, MS , PhD, RN, FAHA , MSHI, RN-BC , PhD, RPh, FAHA , PhD , PhD Lisa Kitko , Colleen K. McIlvennan , Julie T. Bidwell , J. Nicholas Dionne-Odom , Shannon M. Dunlay , Lisa M. Lewis , Ginny Meadows , Elisabeth L.P. Sattler , Richard Schulz , Anna

2020 American Heart Association

2. Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association

Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association | Circulation Search Search Hello Guest! Login to your account Email Password Keep me logged in Search Search June 2020 May 2020 April 2020 March 2020 February 2020 January 2020 This site uses cookies (...) . By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association , PhD, RN, FAHA, Chair , PhD, RN, Vice Chair , MD, MSPH , PhD, NP, FAHA , MD, MPH , PhD, RN, FAHA , PhD, MSN, FAHA , PhD, RN, FAHA , ANP, CNS, FAHA , PhD, MBA, RN Connie White-Williams , Laura P. Rossi , Vera A. Bittner , Andrea Driscoll

2020 American Heart Association

3. Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study

Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Circulation Actions . 2020 May 26;141(21):1693-1703. doi: 10.1161/CIRCULATIONAHA.119.045066. Epub 2020 Apr 17. Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study

2020 EvidenceUpdates

4. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. (Abstract)

Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Three drug classes (mineralocorticoid receptor antagonists [MRAs], angiotensin receptor-neprilysin inhibitors [ARNIs], and sodium/glucose cotransporter 2 [SGLT2] inhibitors) reduce mortality in patients with heart failure with reduced ejection fraction (HFrEF) beyond conventional (...) HFrEF.In this cross-trial analysis, we estimated treatment effects of comprehensive disease-modifying pharmacological therapy (ARNI, β blocker, MRA, and SGLT2 inhibitor) versus conventional therapy (ACE inhibitor or ARB and β blocker) in patients with chronic HFrEF by making indirect comparisons of three pivotal trials, EMPHASIS-HF (n=2737), PARADIGM-HF (n=8399), and DAPA-HF (n=4744). Our primary endpoint was a composite of cardiovascular death or first hospital admission for heart failure; we also

2020 Lancet

5. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. (Abstract)

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear.In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 5050 patients with chronic heart failure (New York Heart Association class II, III, or IV) and an ejection fraction (...) of 691 patients (27.4%) in the vericiguat group and 747 patients (29.6%) in the placebo group were hospitalized for heart failure (hazard ratio, 0.90; 95% CI, 0.81 to 1.00). Death from cardiovascular causes occurred in 414 patients (16.4%) in the vericiguat group and in 441 patients (17.5%) in the placebo group (hazard ratio, 0.93; 95% CI, 0.81 to 1.06). The composite of death from any cause or hospitalization for heart failure occurred in 957 patients (37.9%) in the vericiguat group and in 1032

2020 NEJM

6. Position Statement on COVID-19 and Acute Heart Failure: screening the critically ill

of heart failure, whilst nearly 60% had elevated biochemical markers consistent with acute cardiac injury [4]. In two separate cohort studies from Wuhan [3,5], the proportion of COVID-19 patients with evidence of cardiac injury [as defined by elevated levels of high sensitivity troponin (hsTn) with or without other biochemical markers] ranged from 20 to 28%. In both studies, patients with elevated hsTn were older and more likely to have a range of cardiovascular comorbidities including hypertension (...) , diabetes, coronary artery disease and prior heart failure. In both studies, an elevated hsTn was associated with a marked increase in mortality: 50-60% in those with an elevated hsTn compared with a mortality rate of 5-10% for those who had a normal hsTn during hospitalisation. In addition, COVID-19 patients with elevated hsTn during admission experienced higher rates of acute respiratory distress syndrome (ARDS) necessitating higher rates of non-invasive and invasive ventilation, acute renal failure

2020 Cardiac Society of Australia and New Zealand

7. Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial

Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage (...) any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Circulation Actions . 2020 Apr 21;141(16):1295-1306. doi: 10.1161/CIRCULATIONAHA.119.044865. Epub 2020 Mar 5. Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial

2020 EvidenceUpdates

8. Management of the Hospitalized COVID-19 Patient With Acute Cardiomyopathy or Heart Failure

L. How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People's Hospital. Intensive Care Med 2020;March 11:[Epub ahead of print]. Li H, Zhou Y, Zhang M, Wang H, Zhao Q, Liu J. Updated approaches against SARS-CoV-2. Antimicrob Agents Chemother 2020;March 23:[Epub ahead of print]. Share via: Clinical Topics: Keywords: Acute Coronary Syndrome, Anticoagulants, Arrhythmias, Cardiac, Cardiac Surgical Procedures, Metabolic Syndrome X, Angina, Stable, Heart (...) Management of the Hospitalized COVID-19 Patient With Acute Cardiomyopathy or Heart Failure Feature | Management of the Hospitalized COVID-19 Patient With Acute Cardiomyopathy or Heart Failure - American College of Cardiology ') Search All Types Search or Menu This article was authored by Joel D. Schilling, MD, PhD , Washington University School of Medicine, St. Louis, MO; Ashwin K. Ravichandran, MD, FACC , St. Vincent's Medical Group, Indianapolis, IN; and Stacy A. Mandras, MD, FACC , Oschner

2020 American College of Cardiology

9. Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis Full Text available with Trip Pro

Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis - Canadian Journal of Cardiology Go search , P322-334, March 01, 2020 Powered By Mendeley Share on Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position (...) Columbia, Canada Sean A. Virani Affiliations University of British Columbia, Vancouver, British Columbia, Canada Shelley Zieroth Affiliations University of Manitoba, Winnipeg, Manitoba, Canada DOI: Abstract Cardiac amyloidosis is an under-recognized and potentially fatal cause of heart failure and other cardiovascular manifestations. It is caused by deposition of misfolded precursor proteins as fibrillary amyloid deposits in cardiac tissues. The two primary subtypes of systemic amyloidosis causing

2020 Canadian Cardiovascular Society

10. Is it COVID-19 or Is it Heart Failure? Management of Ambulatory Heart Failure Patients

Is it COVID-19 or Is it Heart Failure? Management of Ambulatory Heart Failure Patients GUIDANCE FROM THE CCS COVID-19 RAPID RESPONSE TEAM Is it COVID-19 or Is it Heart Failure? Management of Ambulatory Heart Failure Patients Introduction To preserve healthcare resources and prevent vulnerable patients from being unnecessarily exposed to healthcare facilities and the Emergency Department (ED), healthcare practitioners are screening patients via virtual assessment (phone, telehealth or regionally (...) available platforms), in order to determine the appropriate diagnostic and treatment approach. The following is simple, practical guidance on patient evaluation and use of laboratory testing. Symptom evaluation The following tool is designed to guide your clinical reasoning to differentiate the likely etiology of symptoms for a patient with known heart failure (HF). It has not been validated, and the final determination must be made using clinical judgement. In cases of uncertainty, patients should

2020 Canadian Cardiovascular Society

11. OUTSMART HF: A Randomized Controlled Trial of Routine Versus Selective Cardiac Magnetic Resonance for Patients With Nonischemic Heart Failure (IMAGE-HF 1B)

OUTSMART HF: A Randomized Controlled Trial of Routine Versus Selective Cardiac Magnetic Resonance for Patients With Nonischemic Heart Failure (IMAGE-HF 1B) OUTSMART HF: A Randomized Controlled Trial of Routine Versus Selective Cardiac Magnetic Resonance for Patients With Nonischemic Heart Failure (IMAGE-HF 1B) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard (...) in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Circulation Actions . 2020 Mar 10;141(10):818-827. doi: 10.1161/CIRCULATIONAHA.119.043964. Epub 2020 Jan 8. OUTSMART HF: A Randomized Controlled Trial of Routine Versus Selective Cardiac Magnetic Resonance for Patients With Nonischemic Heart Failure (IMAGE-HF 1B) , , , , , , , , , , , , , , , , , , , Collaborators, Affiliations Expand Collaborators IMAGE-HF

2020 EvidenceUpdates

12. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. (Abstract)

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment for patients with HFrEF, even those without diabetes.To evaluate the effects of dapagliflozin in patients with HFrEF with and without diabetes.Exploratory analysis of a phase 3 randomized trial (...) conducted at 410 sites in 20 countries. Patients with New York Heart Association classification II to IV with an ejection fraction less than or equal to 40% and elevated plasma N-terminal pro B-type natriuretic peptide were enrolled between February 15, 2017, and August 17, 2018, with final follow-up on June 6, 2019.Addition of once-daily 10 mg of dapagliflozin or placebo to recommended therapy.The primary outcome was the composite of an episode of worsening heart failure or cardiovascular death

2020 JAMA

13. 2020 ACC/HFSA/ISHLT Lifelong Learning Statement for Advanced Heart Failure and Transplant Cardiology Specialists

of selected AHFTC specialists on the basis of background, specialized knowledge, skills, experience, and practice focus (right column). This distinction is particularly relevant to the patient care competencies and recognizes diversity in the focus of practice of AHFTC specialists. Some physicians may specialize in a particular aspect of AHFTC, such as mechanical circulatory support or cardiac transplantation, while others may adopt a practice focused on patients with chronic heart failure with a lesser (...) , there is a growing subspecialization career focus within AHFTC. Specifically, some practitioners limit the scope of their clinical activity to treating patients with advanced heart failure, including those who undergo implantation of a durable ventricular assist device or cardiac transplantation, while others focus on disease management of patients with less advanced heart failure. Thus, although maintenance of some AHFTC competencies is an expectation for all clinical AHFTC specialists, the maintenance

2020 International Society for Heart and Lung Transplantation

14. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis Full Text available with Trip Pro

CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis - Canadian Journal of Cardiology Go search , P159-169, February 01, 2020 Powered By Mendeley CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation (...) . DOI: Abstract In this update, we focus on selected topics of high clinical relevance for health care providers who treat patients with heart failure (HF), on the basis of clinical trials published after 2017. Our objective was to review the evidence, and provide recommendations and practical tips regarding the management of candidates for the following HF therapies: (1) transcatheter mitral valve repair in HF with reduced ejection fraction; (2) a novel treatment for transthyretin amyloidosis

2020 Canadian Cardiovascular Society

15. Cost-Effectiveness of Transitional Care Services After Hospitalization With Heart Failure. (Abstract)

Cost-Effectiveness of Transitional Care Services After Hospitalization With Heart Failure. Patients with heart failure (HF) discharged from the hospital are at high risk for death and rehospitalization. Transitional care service interventions attempt to mitigate these risks.To assess the cost-effectiveness of 3 types of postdischarge HF transitional care services and standard care.Decision analytic microsimulation model.Randomized controlled trials, clinical registries, cohort studies, Centers

2020 Annals of Internal Medicine

16. CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction (Abstract)

CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction The optimal diuretic treatment strategy for patients with acute heart failure and renal dysfunction remains unclear. Plasma carbohydrate antigen 125 (CA125) is a surrogate of fluid overload and a potentially valuable tool for guiding decongestion therapy. The aim of this study was to determine if a CA125-guided diuretic strategy is superior to usual care in terms of short-term renal (...) function in patients with acute heart failure and renal dysfunction at presentation.This multicenter, open-label study randomized 160 patients with acute heart failure and renal dysfunction into 2 groups (1:1). Loop diuretics doses were established according to CA125 levels in the CA125-guided group (n = 79) and in clinical evaluation in the usual-care group (n = 81). Changes in estimated glomerular filtration rate (eGFR) at 72 and 24 hours were the co-primary endpoints, respectively.The mean age

2020 EvidenceUpdates

17. Heart Failure - Systolic Dysfunction

or wall thickness. Gated SPECT may have better inter-observer reliability than echocardiography in assessing ejection fraction. However, the cost and radiation exposure support echocardiography as an appropriate initial evaluation. Functional testing. Exercise stress testing may have a role in the evaluation of some patients with heart failure. Exercise stress testing is useful in evaluating active and significant concomitant coronary artery disease and in assessing functional capacity (...) (dobutamine or dopamine) or phosphodiesterase inhibitors (milrinone) may have a role in the treatment of patients hospitalized for acutely decompensated heart failure who do not respond adequately or in a timely manner to diuretic therapy. Inotropic agents may increase cardiac output and decrease systemic and pulmonary vascular resistance. Although these therapies may improve symptoms and decrease hospitalizations, they are associated with increased mortality. Intermittent bolus or continuous home

2020 University of Michigan Health System

18. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure (Abstract)

Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure While disease-modifying therapies exist for heart failure (HF) with reduced left ventricular ejection fraction (LVEF), few options are available for patients in the higher range of LVEF (>40%). Sacubitril/valsartan has been compared with a renin-angiotensin-aldosterone-system inhibitor alone in 2 similarly designed clinical trials of patients with reduced and preserved LVEF, permitting examination of its effects (...) across the full spectrum of LVEF.We combined data from PARADIGM-HF (LVEF eligibility≤40%; n=8399) and PARAGON-HF (LVEF eligibility≥45%; n=4796) in a prespecified pooled analysis. We divided randomized patients into LVEF categories: ≤22.5% (n=1269), >22.5% to 32.5% (n=3987), >32.5% to 42.5% (n=3143), > 42.5% to 52.5% (n=1427), > 52.5% to 62.5% (n=2166), and >62.5% (n=1202). We assessed time to first cardiovascular death and HF hospitalization, its components, and total heart failure hospitlizations

2020 EvidenceUpdates

19. Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF (Abstract)

older and had more obesity, less coronary disease, and lower estimated glomerular filtration rate and NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels than men. For the primary outcome, the rate ratio for sacubitril-valsartan versus valsartan was 0.73 (95% CI, 0.59-0.90) in women and 1.03 (95% CI, 0.84-1.25) in men (P interaction = 0.017). The benefit from sacubitril-valsartan was attributable to reduction in heart failure hospitalization. The improvement in New York Heart Association (...) Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF Unlike heart failure with reduced ejection fraction, there is no approved treatment for heart failure with preserved ejection fraction, the predominant phenotype in women. Therefore, there is a greater heart failure therapeutic deficit in women compared with men.In a prespecified subgroup analysis, we examined outcomes according to sex

2020 EvidenceUpdates

20. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial Full Text available with Trip Pro

Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go (...) your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Circulation Actions , 141 (2), 90-99 2020 Jan 14 Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial

2020 EvidenceUpdates